Kristian Lovvik Juul-Dam
Overview
Explore the profile of Kristian Lovvik Juul-Dam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeller B, Arad-Cohen N, Cheuk D, De Moerloose B, Navarro J, Hasle H, et al.
Haematologica
. 2024 May;
109(9):2873-2883.
PMID: 38721737
Hyperleukocytosis in pediatric acute myeloid leukemia (AML) is associated with severe complications and an inferior outcome. We report results on patients with hyperleukocytosis included in the NOPHO-DBH AML 2012 study....
2.
Tierens A, Arad-Cohen N, Cheuk D, De Moerloose B, Navarro J, Hasle H, et al.
J Clin Oncol
. 2024 Apr;
42(18):2174-2185.
PMID: 38603646
Purpose: Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response. We designed...
3.
4.
Karlsson L, Cheuk D, De Moerloose B, Hasle H, Jahnukainen K, Juul-Dam K, et al.
Br J Haematol
. 2023 Feb;
201(4):757-765.
PMID: 36762836
A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused by resistant disease (RD). We investigated clinical and biological characteristics in 66 patients with RD from 1013...
5.
Hammer A, Juul-Dam K, Sandahl J, Abrahamsson J, Czogala M, Delabesse E, et al.
Blood Adv
. 2022 Nov;
7(6):1045-1055.
PMID: 36332007
Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic...
6.
Skou A, Juul-Dam K, Ommen H, Hasle H
Br J Haematol
. 2021 Apr;
195(3):310-327.
PMID: 33851435
Longitudinal molecular measurable residual disease (MRD) sampling after completion of therapy serves as a refined tool for identification of imminent relapse of acute myeloid leukaemia (AML) among patients in long-term...
7.
Juul-Dam K, Ommen H, Nyvold C, Walter C, Valerhaugen H, Kairisto V, et al.
Br J Haematol
. 2020 Mar;
190(2):198-208.
PMID: 32175599
Serial assessments of measurable (or minimal) residual disease (MRD) by qPCR may identify nascent relapse in children with acute myeloid leukaemia (AML) and enable pre-emptive therapy. We investigated the kinetics...
8.
Juul-Dam K, Ifversen M, Nyvold C, Hansen M, Hasle H
J Pediatr Hematol Oncol
. 2019 Jun;
41(5):417-419.
PMID: 31238330
Relapse after hematopoietic stem cell transplantation in pediatric acute myeloid leukemia is a fatal event in the majority of cases. Immunotherapy may prevent an impending relapse if instituted at first...
9.
Juul-Dam K, Nyvold C, Valerhaugen H, Zeller B, Lausen B, Hasle H, et al.
Pediatr Blood Cancer
. 2019 Mar;
66(6):e27671.
PMID: 30900388
Background: Measurable/minimal residual disease (MRD) monitoring can predict imminent hematological relapse in acute myeloid leukemia (AML). The majority of childhood AML patients do not harbor fusion genes or mutations applicable...